Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3979189 | Bulletin du Cancer | 2010 | 11 Pages |
Abstract
Despite debulking surgery and taxane/platinum-based chemotherapy, ovarian cancer is the most lethal pelvic gynaecological cancer in western countries, with a 25% 5-years survival. Current histo-clinical prognostic factors are insufficient to capture the heterogeneous clinical outcome of patients. A better molecular characterization of the disease is crucial to refine the prognostic classifications and to identify new therapeutic targets. DNA microarrays, which allow the quantitative measurement of expression level of the whole genome simultaneously in a single tumor sample, have been recently used towards this objective with promising results. Here, we present and discuss the main published studies and the issues to address in the future to allow the expected transfer to clinical practice.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Sabatier R., Finetti P., Cervera N., Birnbaum D., Bertucci F.,